CoChat

Understanding the evolution of macrolides resistance: A mini review

Nor Amdan, Nur Asyura, Shahrulzamri, Nur Atikah, Hashim, Rohaidah, Mohamad Jamil, Norashirene · 2024 · Journal of Global Antimicrobial Resistance
Cited by 64

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Macrolides inhibit the growth of bacterial cells by preventing the elongation of polypeptides during protein biosynthesis and include natural, synthetic, and semi-synthetic products. Elongation prevention occurs by blocking the passage of the polypeptide chain as the macrolides bind at the nascent peptide exit tunnel. OBJECTIVE: Recent data of ribosome profiling via ribo-seq further proves that, other than blocking the polypeptide chain, macrolides are also able to affect the synthesis of individual proteins. Thus, this shows that the mode of action of macrolides is more complex than we initially thought. Since the discovery of macrolides in the 1950s, they have been widely used in veterinary practice, agriculture, and medicine. Due to misuse and overuse of antibiotics, bacteria have acquired resistance against them. Hence, it is of utmost importance for us to fully understand the mode of action of macrolides as well as the mechanisms of resistance against macrolides in order to mitigate antibiotic-resistance issues. RESULTS: Chemical modifications can be performed to improve macrolide potency if we have a better understanding of their mode of action. Furthermore, a complete and detailed understanding of the mode of action of macrolides has remained vague, as new findings have challenged theories that are already in existence-due to this obscurity, research into macrolide modes of action continues to this day. CONCLUSION: In this review, we present an overview of macrolide antibiotics, with an emphasis on the latest knowledge regarding the mode of action of macrolides as well as the mechanisms of resistance employed by bacteria against macrolides.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jgar.2024.07.016

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 68

  1. Doucet-Populaire, 1998, Molecular basis of clarithromycin activity against Mycobacterium avium and Mycobacterium smegmatis, J Antimicrob Chemother, 41, 179, 10.1093/jac/41.2.179 · DOI
  2. Morozumi, 2008, Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia, Antimicrob Agents Chemother, 52, 348, 10.1128/AAC.00779-07 · DOI · Paper page
  3. Alzolibani, 2012, Macrolides in chronic inflammatory skin disorders, Mediators Inflamm, 2012, 10.1155/2012/159354 · doi:10.1155/2012/159354
  4. Cunha, 2006, The atypical pneumonias: clinical diagnosis and importance, Clin Microbiol Infect, 12, 12, 10.1111/j.1469-0691.2006.01393.x · DOI
  5. McGuire, 1952, Ilotycin, a new antibiotic, Antibiot Chemother (Northfield), 2, 281
  6. Oliynyk, 2007, Complete genome sequence of the erythromycin-producing bacterium Saccharopolyspora erythraea NRRL23338, Nat Biotechnol, 25, 447, 10.1038/nbt1297 · DOI · Paper page
  7. Wise, 1955, Origin of erythromycin-resistant strains of Micrococcus pyogenes in infections; bacteriophage types and in vitro resistance of cultures to antibiotics, AMA Arch Intern Med, 95, 419, 10.1001/archinte.1955.00250090057008 · doi:10.1001/archinte.1955.00250090057008
  8. Ball, 1991, The future role and importance of macrolides, J Hosp Infect, 19, 47, 10.1016/0195-6701(91)90217-V · DOI
  9. Puri, 1987, Roxithromycin: a pharmacokinetic review of a macrolide, J Antimicrob Chemother, 20, 89, 10.1093/jac/20.suppl_B.89 · doi:10.1093/jac/20.suppl_b.89
  10. Fernandes, 1988, Comparative in vitro potencies of nine new macrolides, Drugs Exp Clin Res, 14, 445
  11. Kirst, 1993, Semi-synthetic derivatives of erythromycin, Prog Med Chem, 30, 57, 10.1016/S0079-6468(08)70375-8 · DOI
  12. Jelić, 2016, From erythromycin to azithromycin and new potential ribosome-binding antimicrobials, Antibiotics (Basel), 5
  13. Arsic, 2018, 16-membered macrolide antibiotics: a review, Int J Antimicrob Agents, 51, 283, 10.1016/j.ijantimicag.2017.05.020 · DOI · Paper page
  14. Cui, 2011, Recent advances in the field of 16-membered macrolide antibiotics, Mini Rev Med Chem, 11, 1009, 10.2174/138955711797247734 · doi:10.2174/138955711797247734
  15. Ackermann, 2003, Drugs of the 21st century: telithromycin (HMR 3647)–the first ketolide, J Antimicrob Chemother, 51, 497, 10.1093/jac/dkg123 · DOI
  16. Farrell, 2015, Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012, Antimicrob Agents Chemother, 59, 2432, 10.1128/AAC.04568-14 · doi:10.1128/aac.04568-14
  17. Hammerschlag, 2008, Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections, Expert Opin Investig Drugs, 17, 387, 10.1517/13543784.17.3.387 · DOI
  18. Kannan, 2012, Selective protein synthesis by ribosomes with a drug-obstructed exit tunnel, Cell, 151, 508, 10.1016/j.cell.2012.09.018 · DOI
  19. Lenz, 2021, Macrolides: from Toxins to Therapeutics, Toxins (Basel), 13, 10.3390/toxins13050347 · DOI
  20. Tu, 2005, Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance, Cell, 121, 257, 10.1016/j.cell.2005.02.005 · DOI · Paper page
  21. Usary, 2001, Erythromycin inhibition of 50S ribosomal subunit formation in Escherichia coli cells, Mol Microbiol, 40, 951, 10.1046/j.1365-2958.2001.02438.x · DOI
  22. Dunkle, 2010, Structures of the Escherichia coli ribosome with antibiotics bound near the peptidyl transferase center explain spectra of drug action, Proc Natl Acad Sci USA, 107, 17152, 10.1073/pnas.1007988107 · DOI · Paper page
  23. Schlünzen, 2001, Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria, Nature, 413, 814, 10.1038/35101544 · DOI · Paper page
  24. Menninger, 1982, Erythromycin, carbomycin, and spiramycin inhibit protein synthesis by stimulating the dissociation of peptidyl-tRNA from ribosomes, Antimicrob Agents Chemother, 21, 811, 10.1128/AAC.21.5.811 · DOI · Paper page
  25. Otaka, 1975, Release of (oligo) peptidyl-tRNA from ribosomes by erythromycin A, Proc Natl Acad Sci USA, 72, 2649, 10.1073/pnas.72.7.2649 · DOI
  26. Clancy, 1996, Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes, Mol Microbiol, 22, 867, 10.1046/j.1365-2958.1996.01521.x · DOI · Paper page
  27. Tait-Kamradt, 1997, mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae, Antimicrob Agents Chemother, 41, 2251, 10.1128/AAC.41.10.2251 · DOI · Paper page
  28. Barthélémy, 1984, Enzymic hydrolysis of erythromycin by a strain of Escherichia coli. A new mechanism of resistance, J Antibiot (Tokyo), 37, 1692, 10.7164/antibiotics.37.1692 · DOI
  29. Chesneau, 2007, Resistance phenotypes conferred by macrolide phosphotransferases, FEMS Microbiol Lett, 269, 317, 10.1111/j.1574-6968.2007.00643.x · DOI · Paper page
  30. González-Plaza, 2017, Udiković-Kolić N. Functional repertoire of antibiotic resistance genes in antibiotic manufacturing effluents and receiving freshwater sediments, Front Microbiol, 8, 2675, 10.3389/fmicb.2017.02675 · DOI
  31. Kono, 1992, Purification and characterization of macrolide 2′-phosphotransferase type II from a strain of Escherichia coli highly resistant to macrolide antibiotics, FEMS Microbiol Lett, 76, 89
  32. Lambert, 2005, Bacterial resistance to antibiotics: modified target sites, Adv Drug Deliv Rev, 57, 1471, 10.1016/j.addr.2005.04.003 · DOI · Paper page
  33. Muto, 1987, The guanine and cytosine content of genomic DNA and bacterial evolution, Proc Natl Acad Sci USA, 84, 166, 10.1073/pnas.84.1.166 · DOI · Paper page
  34. Noguchi, 1998, Expression of the mphB gene for macrolide 2′-phosphotransferase II from Escherichia coli in Staphylococcus aureus, FEMS Microbiol Lett, 159, 337
  35. O'Hara, 1989, Purification and characterization of macrolide 2′-phosphotransferase from a strain of Escherichia coli that is highly resistant to erythromycin, Antimicrob Agents Chemother, 33, 1354, 10.1128/AAC.33.8.1354 · DOI · Paper page
  36. O'Hara, 1996, Reaction of roxithromycin and clarithromycin with macrolide-inactivating enzymes from highly erythromycin-resistant Escherichia coli, Antimicrob Agents Chemother, 40, 1036, 10.1128/AAC.40.4.1036 · doi:10.1128/aac.40.4.1036
  37. Ounissi, 1985, Nucleotide sequence of the gene ereA encoding the erythromycin esterase in Escherichia coli, Gene, 35, 271, 10.1016/0378-1119(85)90005-8 · DOI
  38. Xing, 2015, ErmF and ereD are responsible for erythromycin resistance in Riemerella anatipestifer, PLoS ONE, 10, 10.1371/journal.pone.0131078 · DOI
  39. Yong, 2009, Characterization of a new metallo-beta-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India, Antimicrob Agents Chemother, 53, 5046, 10.1128/AAC.00774-09 · DOI · Paper page
  40. Su, 2018, Ribosome protection by antibiotic resistance ATP-binding cassette protein, Proc Natl Acad Sci USA, 115, 5157, 10.1073/pnas.1803313115 · DOI · Paper page
  41. Wagman, 1980, Antibiotic from Micromonospora, Annu Rev Microbiol, 34, 537, 10.1146/annurev.mi.34.100180.002541 · doi:10.1146/annurev.mi.34.100180.002541
  42. Waitz, 1971, Biological activity of megalomicin A phosphate, a water-soluble salt of megalomicin A, J Antibiot (Tokyo), 24, 310, 10.7164/antibiotics.24.310 · doi:10.7164/antibiotics.24.310
  43. Sothiselvam, 2016, Binding of macrolide antibiotics leads to ribosomal selection against specific substrates based on their charge and size, Cell Rep, 16, 1789, 10.1016/j.celrep.2016.07.018 · DOI · Paper page
  44. Dinos, 2017, The macrolide antibiotic renaissance, Br J Pharmacol, 174, 2967, 10.1111/bph.13936 · DOI · Paper page
  45. Almutairi, 2017, Co-produced natural ketolides methymycin and pikromycin inhibit bacterial growth by preventing synthesis of a limited number of proteins, Nucleic Acids Res, 45, 9573, 10.1093/nar/gkx673 · DOI
  46. Han, 2020, Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children, Pak J Med Sci, 36, 156
  47. Pereyre, 2016, Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment, Front Microbiol, 7, 974, 10.3389/fmicb.2016.00974 · DOI · Paper page
  48. Kocsmár, 2021, Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides, Nat Commun, 12, 2255, 10.1038/s41467-021-22557-7 · DOI
  49. Castro-Filice, 2014, Azithromycin is able to control Toxoplasma gondii infection in human villous explants, J Transl Med, 12, 132, 10.1186/1479-5876-12-132 · doi:10.1186/1479-5876-12-132
  50. Gabashvili, 2001, The polypeptide tunnel system in the ribosome and its gating in erythromycin resistance mutants of L4 and L22, Mol Cell, 8, 181, 10.1016/S1097-2765(01)00293-3 · DOI · Paper page
  51. Javed, 2017, The ribosome and its role in protein folding: looking through a magnifying glass, Acta Crystallogr D Struct Biol, 73, 509, 10.1107/S2059798317007446 · DOI
  52. Arévalo, 1988, Protein components of the erythromycin binding site in bacterial ribosomes, J Biol Chem, 263, 58, 10.1016/S0021-9258(19)57355-0 · DOI · Paper page
  53. Tenson, 2003, The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome, J Mol Biol, 330, 1005, 10.1016/S0022-2836(03)00662-4 · DOI · Paper page
  54. Menninger, 1985, Functional consequences of binding macrolides to ribosomes, J Antimicrob Chemother, 16, 23, 10.1093/jac/16.suppl_A.23 · DOI
  55. Sothiselvam, 2014, Macrolide antibiotics allosterically predispose the ribosome for translation arrest, Proc Natl Acad Sci USA, 111, 9804, 10.1073/pnas.1403586111 · DOI · Paper page
  56. Kannan, 2014, The general mode of translation inhibition by macrolide antibiotics, Proc Natl Acad Sci USA, 111, 15958, 10.1073/pnas.1417334111 · DOI · Paper page
  57. Li, 2012, The anti-Shine-Dalgarno sequence drives translational pausing and codon choice in bacteria, Nature, 484, 538, 10.1038/nature10965 · DOI · Paper page
  58. Leclercq, 1991, Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification, Antimicrob Agents Chemother, 35, 1267, 10.1128/AAC.35.7.1267 · DOI · Paper page
  59. Horiki, 2009, Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan, Helicobacter, 14, 86, 10.1111/j.1523-5378.2009.00714.x · doi:10.1111/j.1523-5378.2009.00714.x
  60. Karamanolis, 2014, The evolution of Helicobacter pylori antibiotics resistance over 10 years in Greece, Digestion, 90, 229, 10.1159/000369898 · doi:10.1159/000369898
  61. Hunt, 2011, Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline, J Clin Gastroenterol, 45, 383, 10.1097/MCG.0b013e31820fb8f6 · DOI · Paper page
  62. Xiao, 2015, Bacterial-resistance among outpatients of county hospitals in China: significant geographic distinctions and minor differences between central cities, Microbes Infect, 17, 417, 10.1016/j.micinf.2015.02.001 · doi:10.1016/j.micinf.2015.02.001
  63. Vester, 2001, Macrolide resistance conferred by base substitutions in 23S rRNA, Antimicrob Agents Chemother, 45, 1, 10.1128/AAC.45.1.1-12.2001 · DOI · Paper page
  64. Wilson, 2005, Species-specific antibiotic-ribosome interactions: implications for drug development, Biol Chem, 386, 1239, 10.1515/BC.2005.141 · DOI · Paper page
  65. Pihlajamäki, 2002, Ribosomal mutations in Streptococcus pneumoniae clinical isolates, Antimicrob Agents Chemother, 46, 654, 10.1128/AAC.46.3.654-658.2002 · DOI
  66. Lovmar, 2009, Erythromycin resistance by L4/L22 mutations and resistance masking by drug efflux pump deficiency, EMBO J, 28, 736, 10.1038/emboj.2009.17 · DOI
  67. Wekselman, 2017, The ribosomal protein uL22 modulates the shape of the protein exit tunnel, Structure, 25, 1233, 10.1016/j.str.2017.06.004 · DOI
  68. Golkar, 2018, Berghuis AM. Look and outlook on enzyme-mediated macrolide resistance, Front Microbiol, 9, 1942, 10.3389/fmicb.2018.01942 · DOI

Cited by

See all 64

Metadata

Authors
Nor Amdan, N. A., Shahrulzamri, N. A., Hashim, R., & Mohamad Jamil, N.
Venue
Journal of Global Antimicrobial Resistance
Publisher
Elsevier BV
Published
2024-09
Volume
38
Pages
368-375
ISSN
2213-7165
Cited by
64
References
8
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Understanding the evolution of macrolides resistance: A mini review. https://app.cochat.ai/papers/10.1016/j.jgar.2024.07.016
The paper
Nor Amdan, N. A., Shahrulzamri, N. A., Hashim, R., & Mohamad Jamil, N. (2024). Understanding the evolution of macrolides resistance: A mini review. Journal of Global Antimicrobial Resistance. https://doi.org/10.1016/j.jgar.2024.07.016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.